Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

NCT02773524 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.

NCT NCT02773524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02773524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2016
Completion date
December 31, 2022
Enrollment
250 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

gastro-oesophageal cancer